Levine Alan M
Known title: DirectorCIK: 0001766833
Associated companies
Transaction History
| AXGN | ▲ Buy | Option Exercise | 14,150 | $0 | 6/19/2026 | View on chart |
| AXGN | ▼ Sell | Open Market | 4,073 | $43K | 6/9/2025 | View on chart |
| AXGN | ▲ Buy | Option Exercise | 11,904 | $0 | 9/1/2024 | View on chart |
| AXGN | ▲ Buy | Grant | 10,653 | — | 6/6/2024 | View on chart |
| AXGN | ▲ Buy | Option Exercise | 6,459 | $0 | 6/1/2023 | View on chart |
| AXGN | ▲ Buy | Option Exercise | 3,036 | $0 | 6/1/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 12, 2026
Axogen Receives New Analyst Coverage and Valuation Upside
Axogen has attracted new analyst coverage from Robinhood and B of A Securities, both issuing bullish notes and setting price targets around $52. A Yahoo analysis suggests the stock may be about 26% undervalued on cash‑flow grounds, while the company has fallen 22.6% in the past month. These developments highlight renewed investor interest and potential upside relative to recent price action.
Axogen Receives New Analyst Coverage and Valuation Upside. Axogen has attracted new analyst coverage from Robinhood and B of A Securities, both issuing bullish notes and setting price targets around $52. A Yahoo analysis suggests the stock may be about 26% undervalued on cash‑flow grounds, while the company has fallen 22.6% in the past month. These developments highlight renewed investor interest and potential upside relative to recent price action.